Format

Send to

Choose Destination
Br J Haematol. 2018 Dec;183(5):717-726. doi: 10.1111/bjh.15603. Epub 2018 Nov 8.

Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.

Author information

1
Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.
2
Unit of Epidemiology and Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
3
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
4
Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
5
Department of Haematology, Odense University Hospital, Odense, Denmark.
6
Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.
7
Department of Haematology, Holstebro Hospital, Holstebro, Denmark.
8
Department of Haematology, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
9
Department of Haematology, Zealand University Hospital, Roskilde, Denmark.
10
Department of Haematology, Sygehus Lillebaelt, Vejle, Denmark.
11
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
12
Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark.
13
Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.

Abstract

Cardiotoxicity is a known risk of anthracycline treatment. However, the relative contribution of anthracyclines to the development of congestive heart failure (CHF), when included in a poly-chemotherapy regimen, is unclear. We examined cardiotoxicity in adult patients with diffuse large B-cell lymphoma and follicular lymphoma undergoing first-line immunochemotherapy from 2000-2012. In total, 2440 patients without previous heart disease were identified from the Danish Lymphoma Registry, of which 1994 (81·7%) were treated with anthracycline-containing chemotherapy [R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) or R-CHOEP (R-CHOP + etoposide)] and 446 (18·3%) were treated without anthracyclines (reference group). Compared to the reference group, the adjusted hazard ratio of CHF after 3-5 cycles of R-CHOP/CHOEP was 5·0 [95% confidence interval (CI) 1·4; 18·5], 6 cycles 6·8 (95% CI 2·0; 23·3) and >6 cycles 13·4 (95% CI 4·0; 45·0). The cumulative 5-year risk of CHF with all-cause mortality as competing risk was 4·6% after 3-5 cycles of R-CHOP/CHOEP, 4·5% after 6 and 7·9% after more than 6 cycles. Cumulative 5-year risk for patients treated without anthracyclines was 0·8%. Using anthracyclines in first-line lymphoma treatment increases risk of CHF in patients without previous history of heart disease. In particular, treatment with >6 cycles of R-CHOP/CHOEP is associated with a significant increase in CHF rate.

KEYWORDS:

cardiology; chemotherapy; epidemiology; haemotoxicity; lymphomas

PMID:
30406945
DOI:
10.1111/bjh.15603

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center